SCHEMBL13737672

SCHEMBL13737672

CC1(NC(=O)OC(C)(C)C)CCN(C(=O)O)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.36
RORC P51449 2/20 0.35
MEN1 O00255 1/20 0.35
MAPK1 P28482 1/20 0.35
KMT2A Q03164 1/20 0.35
SPR P35270 1/20 0.34
CYP4F2 P78329 1/20 0.33
CYP4A11 Q02928 1/20 0.33
CCR1 P32246 1/20 0.33
CACNA1H O95180 1/20 0.33
HDAC2 Q92769 2/20 0.32
HDAC1 Q13547 1/20 0.32
PIK3R1 P27986 2/20 0.32
PIK3CA P42336 2/20 0.32
PIK3CD O00329 1/20 0.32
PIK3CB P42338 1/20 0.32
USP2 O75604 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
DPP8 Q6V1X1 1/20 0.32
DPP9 Q86TI2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3295187 1.00 EPHX2 (0.36) EPHX2RORCMEN1MAPK1KMT2A
SCHEMBL27947023 1.00 EPHX2 (0.36) EPHX2RORCMEN1MAPK1KMT2A
SCHEMBL15913346 0.91 CA1 (0.35) EPHX2RORCMEN1MAPK1KMT2A
SCHEMBL21789080 0.88 EPHX2 (0.45) EPHX2HDAC2HDAC1PIK3R1PIK3CA
SCHEMBL14829193 0.87 MEN1 (0.39) EPHX2RORCMEN1MAPK1KMT2A
SCHEMBL1994522 0.81 USP2 (0.47) EPHX2HDAC2HDAC1USP2SMN1; SMN2
SCHEMBL16887631 0.81 CYP4F2 (0.40) EPHX2RORCMEN1MAPK1KMT2A
SCHEMBL28189059 0.81 CYP4F2 (0.33) EPHX2MEN1MAPK1KMT2ACYP4F2
SCHEMBL28802934 0.79 RORC (0.36) EPHX2RORCMEN1MAPK1KMT2A
SCHEMBL23120825 0.78 CYP4F2 (0.39) EPHX2MEN1KMT2ACYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2678329-B1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2015-11-18 EP disclosed
US-8889704-B2 Triazolopyridine compounds as PIM kinase inhibitors ARRAY BIOPHARMA INC. (US) 2014-11-18 US disclosed
US-20140005213-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-01-02 US disclosed
EP-2678329-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS Array Biopharma, Inc. (US) 2014-01-01 EP disclosed
WO-2012154274-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2012-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140005213-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS PIM1, PIM2, PIM3 EPHX2 4778/4885RORC 2261/4885MEN1 2952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.